Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Opdivo

NICE ‘yes’ for BMS skin cancer drug Opdivo

January 22, 2016
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, melanoma, nivolumab, opdivo, skin cancer

NICE has approved Bristol-Myers Squibb’s skin cancer immunotherapy Opdivo (nivolumab) in final draft guidance as monotherapy for NHS patients in England …

News
Chemotherapy

A brighter future for the Cancer Drugs Fund?

January 14, 2016
Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Prostate Cancer UK

In November 2015, NICE and NHS England announced proposed changes to the operation of the Cancer Drugs Fund. This is …

Feature
Janssen Velcade

NICE recommends Velcade for MCL, and three diabetes drugs

December 23, 2015
Sales and Marketing Forxiga, NICE, Velcade, invokana, jardiance, mantel cell lymphoma, mcl

NICE has published final guidance recommending Velcade (bortezomib) as a treatment for previously untreated mantle cell lymphoma (MCL).  In the …

News

New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs

December 16, 2015
Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin

NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …

News
NHS sign

NICE rejects BMS cancer drug in draft guidance

December 16, 2015
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …

News
Kadcyla

NICE says no to NHS funding for Kadcyla

December 16, 2015
Research and Development, Sales and Marketing Breast Cancer Now, Kadcyla, NHS, NICE, Roche, advanced breast cancer, breast cancer

NICE has turned down Roche’s application for NHS funding for Kadcyla as a treatment for a type of advanced breast …

News
Novartis image

Novartis earns provisional NICE yes for Entresto

December 11, 2015
Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure

NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …

News
Lynparza

NICE recommends AstraZeneca’s Lynparza after price reduction

December 11, 2015
Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer

NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …

News

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015
Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …

News
Novartis image

NICE backtracks on Novartis Farydak decision

December 4, 2015
Medical Communications, Sales and Marketing Farydak, NICE, Novartis, panobinostat

NICE has reversed its earlier decision to reject the Novartis drug Farydak as an NHS treatment for people with multiple …

News

NICE turns down bone disorder drug for NHS

December 3, 2015
Research and Development Alexion, NICE, Strensiq

NICE has published draft guidance as part of its highly specialised technologies programme, not recommending Alexion Pharma’s Strensiq (asfotase alfa) …

News

Personalised care key to diabetes management, says NICE

December 2, 2015
Research and Development NICE, NICE guidelines, diabetes, type 2 diabetes

UK drugs regulator NICE has published updated guidelines on type 2 diabetes, saying that taking an individualised approach to care …

News
dna

Companies face mixed fortunes in ultra-orphan approvals

November 26, 2015
Medical Communications, Research and Development BioMarin, Duchenne Muscular Dystrophy, FDA, Genzyme, NICE, ultra-orphan drugs

UK regulator NICE has recommended Vimizin, a drug for a very rare genetic disorder, after the manufacturer and NHS England …

Feature
nhs_england_and_nice_logos

NHS England and NICE announce plans for new Cancer Drugs Fund

November 19, 2015
Medical Communications, Research and Development Cancer Drugs Fund, NHS England, NICE

A 12-week consultation on draft proposals for a revamped Cancer Drugs Fund (CDF) has been launched by NHS England and NICE, …

News
bayer_cross_2

NICE decision restricts Bayer’s Xofigo to select prostate cancer patients

November 19, 2015
Research and Development, Sales and Marketing Bayer, NICE, prostate cancer

NICE has issued its Final Appraisal Determination (FAD) recommending Bayer’s Xofigo (radium-223 dichloride) for use on the NHS in England …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026